Forum Financial Management LP Buys New Position in Masimo Co. (NASDAQ:MASI)

Forum Financial Management LP acquired a new position in Masimo Co. (NASDAQ:MASI) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,314 shares of the medical equipment provider’s stock, valued at approximately $217,000.

A number of other large investors have also recently made changes to their positions in MASI. Smartleaf Asset Management LLC raised its stake in Masimo by 31.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 60 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 64 shares during the period. Blue Trust Inc. lifted its stake in shares of Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 71 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in Masimo by 0.8% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider’s stock worth $1,622,000 after buying an additional 82 shares during the period. Finally, Thrivent Financial for Lutherans increased its stake in Masimo by 0.8% in the 4th quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider’s stock worth $1,728,000 after buying an additional 83 shares in the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the sale, the director now directly owns 16,581 shares of the company’s stock, valued at $2,754,601.53. This represents a 11.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the sale, the chief operating officer now directly owns 24,172 shares of the company’s stock, valued at approximately $4,048,568.28. The trade was a 55.38 % decrease in their position. The disclosure for this sale can be found here. 9.70% of the stock is owned by corporate insiders.

Masimo Stock Up 1.9 %

Shares of NASDAQ MASI opened at $152.07 on Wednesday. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $194.88. The firm’s 50-day moving average price is $166.89 and its 200-day moving average price is $165.11. The stock has a market capitalization of $8.22 billion, a price-to-earnings ratio of 104.88 and a beta of 1.28.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38. The business had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. On average, equities research analysts anticipate that Masimo Co. will post 4.1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Thursday, April 10th. Wells Fargo & Company lifted their target price on Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Piper Sandler increased their price target on Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, Raymond James lifted their price objective on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, Masimo currently has a consensus rating of “Moderate Buy” and an average target price of $194.80.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.